A Quick Double Down On Esperion

by Biotech Newsroom


Word Count: 2,188 words, Reading Time: 10 minutes. Not financial advice, do your own due diligence, for entertainment purposes only.

Subscribers: Substack is telling me this post is too long for email so please load in browser if the bottom cuts off before my signature.

A little bit of a shorter article this week as my son was on Spring Break so I took some time off to be with him.

On February 3rd, I wrote my first ever article on Esperion ahead of what I thought should be a multi-year period of 30%+ annual revenue growth:



Source link

You may also like

Houston, TX – (EmailWire) — The Biotech Times™ aggregates, publishes and distributes news about the Biotech Industry. In association with EmailWire™, The Biotech Times, helps businesses and organizations in the industry with press release distribution. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us through the following messaging apps:

Free Magazines

Recent Articles

BioTech Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC